Hemostemix (CVE:HEM) Hits New 52-Week Low – What’s Next?

Hemostemix Inc. (CVE:HEM) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as C$0.06 and last traded at C$0.07, with a volume of 70000 shares changing hands. The stock had previously closed at C$0.07.

Hemostemix Trading Up 7.7%

The stock has a market cap of C$13.19 million, a P/E ratio of -2.59 and a beta of 0.25. The company has a debt-to-equity ratio of -99.52, a quick ratio of 0.48 and a current ratio of 1.54. The stock’s fifty day moving average is C$0.08 and its 200 day moving average is C$0.09.

About Hemostemix

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.